Aranscia’s Houda Hachad Interviewed in the Journal of Clinical Pathways Regarding PGx Testing in Oncology

In this interview, Houda Hachad, PharmD, M.Res, highlights best practices for implementing PGx testing in oncology and what barriers institutions such as cancer centers and hospitals face in trying to expand this testing.

“First, if we go back to the case of DPYD testing, for example… there is lack of education or knowledge among the community—including the oncology care team—that these tests are available, that we have tools, have established guidelines, that there are standards, and therefore they are ready for implementation.” – Houda Hachad, Vice President of Clinical Operations at Aranscia

Click here to watch the interview in the Journal of Clinical Pathways.